drugset / Trial / NCT00734149
Bortezomib With Melphalan and Prednisone for Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the efficacy of bortezomib in combination with melphalan and prednisone to achieve complete responses for patients with previously untreated multiple myeloma compared to an historical control group. This trial will also evaluate the safety and toxicity of this regimen as well as evaluate the duration of response of this regimen.
Timeline
- Start
- 2004-07
- Primary completion
- 2008-02
- Completion
- 2008-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Intravenous |
| Subject | Melphalan | Small molecule | 6 mg/m2 | Oral |
| Subject | Prednisone | Other / unclassified | 60 mg/m2 | Oral |